药物随机对照试验的二次发表中20%未提供相对于主要发表的新结果
该研究检索2014年发表于五个高影响因子医学期刊的随机对照试验,通过注册号识别二次发表,评估二次发表提供新结果的比例。共识别144篇主要发表,94篇(65%)在主要发表后30个月内有至少一篇二次发表;其中20%仅报告主要发表中已有的结果,35%报告非预设分析或非基于系统综述的汇总分析。结论认为高影响因子期刊发表的药物随机对照试验多数有二次发表,超过半数二次发表提供已报告结果或非预设分析结果。
要点
- 144篇主要发表中94篇(65%)在30个月内有至少一篇二次发表。
- 20%的二次发表仅报告主要发表中已有的结果。
- 35%的二次发表报告非预设分析或非基于系统综述的汇总分析。
核心结论
- 高影响因子期刊发表的药物随机对照试验多数有二次发表,超过半数二次发表提供已报告结果或非预设分析结果。
研究设计与样本
- 检索2014年发表于五个影响因子最高的医学期刊的随机对照试验,通过注册号识别每篇主要发表的二次发表。
- 共识别144篇主要发表;主要结局指标为二次发表中报告主要发表已报告结果和/或非预设分析和/或汇总未通过系统综述识别研究的Meta分析的比例。
主要发现
- 144篇主要发表中94篇(65%)在主要发表后30个月内有至少一篇二次发表。
- 二次发表中20%仅报告主要发表中已有的结果,35%报告非预设分析或非基于系统综述的汇总分析。
- 随机化试验参与者数量多与有至少一篇二次发表相关:>1,000例 vs ≤500例的OR为3.2(95%CI 1.1-9.3)。
- 研究生物制品 vs 非生物制品的OR为4.8(95%CI 1.4-16.3)。
- 心脏病学领域 vs 其他领域的OR为7.6(95%CI 1.46-39.8)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of the study was to estimate the proportion of secondary publications of randomized controlled trials (RCTs) that provide new results relative to the primary publication. STUDY DESIGN AND SETTING: We searched for RCTs published in 2014 in the five medical journals with the highest impact factors. Secondary publications for each primary publication were then identified by their registration number. The main outcome measure was the proportion of secondary publications providing results already reported in the primary publication and/or nonprespecified analyses and/or a meta-analysis pooling results of studies not identified by systematic review. RESULTS: A total of 144 primary publications were identified; 94 (65%) had at least one secondary publication within 30 months after a primary publication. Of the secondary publications, 20% reported only results present in the primary publication, and 35% reported results not prespecified or pooled analyses not based on a systematic review. Factors associated with having at least one secondary publication were a large number of randomized trial participants (odds ratio [95% confidence interval]: 3.2 [1.1-9.3] for trials with >1,000 vs. ≤500 participants), investigating a biologic product (4.8 [1.4‒16.3] vs. a nonbiologic product) and cardiologic field vs. other fields (7.6 [1.46-39.8]). CONCLUSION: Most drug RCTs with results published in high-impact-factor journals had secondary publications. More than half of these secondary publications provided results already reported in the primary publication or results of nonprespecified analyses.
引用
- Lai C, Sbidian E, Giraudeau B, et al. Twenty percent of secondary publications of randomized controlled trials of drugs did not provide new results relative to the primary publication. J Clin Epidemiol. 2019. PMID: 31546006. doi:10.1016/j.jclinepi.2019.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。